Dexcel Pharma
VC Fund
Jerusalem, Israel
Dexcel Pharma is a VC fund in Jerusalem focused on Health Care and Biotechnology. Dexcel Pharma is Israel’s largest private pharmaceutical company. Founded in 1968, they develop, manufacture and market value-added branded and generic pharmaceuticals. With a diverse product portfolio that spans more than 55 branded and generic products in over 140 dosage forms, our products are sold in the US, the UK, and Germany, viasubsidiaries and through a trusted network of partners in more than 30 countries worldwide.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Dexcel Pharma invests in
Stages Dexcel Pharma invests in
Countries Dexcel Pharma invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Dan Oren
|
|||
|
Ilan Oren
|
|||
|
Tomer Gold
|
|||
|
Tzuki Harush
|
|||
|
Uri Oren
|
Investment Focus
Industry
- Health Care 3 (43%)
- Biotechnology 3 (43%)
- Medical 2 (29%)
- Therapeutics 2 (29%)
- Biopharma 1 (14%)
Stage
- Series A 3 (43%)
- Series B 2 (29%)
- Series C 1 (14%)
- Private Equity 1 (14%)
Country
- United States 3 (43%)
- Israel 2 (29%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dan Oren
Founder, President & Chief Executive Officer
|
Founder, President & Chief Executive Officer | Total investments: 0 | Find email | |
|
Ilan Oren
Vice President, Business Development
|
Vice President, Business Development | Total investments: 0 | Find email | |
|
Tomer Gold
Vice President, Research & Development
|
Vice President, Research & Development | Total investments: 0 | Find email | |
|
Tzuki Harush
Vice President, Finance and Chief Financial Officer
|
Vice President, Finance and Chief Financial Officer | Total investments: 0 | Find email | |
|
Uri Oren
Vice President, Chief Operating Officer
|
Vice President, Chief Operating Officer | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Syremis Therapeutics
|
Syremis Therapeutics is developing novel medicines to make a profound impact on the treatment of mental health disorders. | $165M / Series A / Dec 18, 2025 | |
Kriya Therapeutics
|
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases. | $270M / Series C / May 16, 2022 | |
BrainQ
|
BrainQ develops a platform for precision neurology therapies to treat the impaired brain using a BCI-based approach. The company was founded in 2016 and is headquartered in Jerusalem, Yerushalayim, Israel. | $40M / Series B / Aug 16, 2021 | |
|
Kriya Therapeutics
|
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases. | $100M / Series B / Jul 14, 2021 | |
Immunai
|
Immunai is a biotech company that combines single-cell genomics with ML algorithms to enable high-resolution profiling of the immune system.Immunai's mission is to map the entire immune system and its functions using single-cell genomics and machine learning. Immunai leverages single-cell technologies to profile cells from a blood sample,and uses machine-learning algorithms (powered by its proprietary database) to map the hundreds of cell types and their states to create an immune profile. They work on biomarker discovery and insights that identify how a cell responds to its changing environment.The company is located in New York City, San Francisco, and Tel Aviv, Israel. | $60M / Series A / Feb 11, 2021 | |
|
Kriya Therapeutics
|
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases. | $80.5M / Series A / May 12, 2020 | |
Roivant Sciences
|
Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates.Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. Roivant does this by building Vants - nimble, entrepreneurial biotech andhealthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying the technology. In addition to its biopharmaceutical subsidiaries, Roivant also builds technology-focused Vants focused on improving the process of developing and commercializing medicines. | $93M / Private Equity / May 01, 2014 |
Co-Investors
QVT Financial
5 deals together
Patient Square Capital
4 deals together
Bluebird Ventures
3 deals together
Foresite Capital
3 deals together
JDRF T1D Fund
3 deals together
Narya Capital
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Dexcel Pharma invest in?
Dexcel Pharma invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Dexcel Pharma?
Public channels for Dexcel Pharma include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Dexcel Pharma?
The team at Dexcel Pharma includes Dan Oren (Founder, President & Chief Executive Officer), Ilan Oren (Vice President, Business Development) and Tomer Gold (Vice President, Research & Development), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
